Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;45(4):816-826.
doi: 10.1002/hed.27294. Epub 2023 Jan 16.

Genomic profiling and precision medicine in complex ameloblastoma

James C Gates  1 , Allison P Clark  2 , Elliot Cherkas  3 , Aditya V Shreenivas  4 , Dennis Kraus  5 , Natalie Danzinger  2 , Richard S P Huang  2 , Jennifer Johnson  6 , Jeffrey S Ross  2   7   8
Affiliations

Genomic profiling and precision medicine in complex ameloblastoma

James C Gates et al. Head Neck. 2023 Apr.

Abstract

Background: Ameloblastoma may present a significant treatment challenge in the locally advanced, recurrent and metastatic setting. Comprehensive genomic profiling (CGP) can identify targetable genomic alterations to aid in treatment.

Methods: Ameloblastoma samples were sequenced using hybrid-capture based sequencing. A systematic literature review was performed to examine outcomes in studies employing targeted treatment in ameloblastoma.

Results: We reviewed 14 cases of Ameloblastoma using CGP. There were six patients with activating BRAF mutations, five with PIK3CA, five with SMO, four with FGFR2, one with EGFR, and one with ROS1. All cases were MSI stable and the median TMB was 2.5 mutations/Mb. A separate literature review of clinical outcomes in ameloblastoma showed a predominance of at least partial response to targeted treatment (7/12 cases).

Conclusion: CGP is helpful in identifying specific driver mutations in patients with complex ameloblastoma. Targeted treatment has been employed with success in achieving treatment response.

Keywords: ameloblastoma; genomic profiling; molecular markers; next generation sequencing; odontogenic cysts and tumors; precision medicine; targeted treatment.

PubMed Disclaimer

References

REFERENCES

    1. Hendra FN, van Cann EM, Helder MN, et al. Global incidence and profile of ameloblastoma: a systematic review and meta-analysis. Oral Dis. 2020;26(1):12-21.
    1. Adeel M, Rajput MSA, Arain AA, Baloch M, Khan M. Ameloblastoma: management and outcome. Cureus. 2018;10(10):e3437.
    1. Brazis PW, Miller NR, Lee AG, Holliday MJ. Neuro-ophthalmologic aspects of ameloblastoma. Skull Base Surg. 1995;5(4):233-244.
    1. Petrovic ID, Migliacci J, Ganly I, et al. Ameloblastomas of the mandible and maxilla. Ear Nose Throat J. 2018;97(7):E26-e32.
    1. Yang R, Liu Z, Gokavarapu S, Peng C, Ji T, Cao W. Recurrence and cancerization of ameloblastoma: multivariate analysis of 87 recurrent craniofacial ameloblastoma to assess risk factors associated with early recurrence and secondary ameloblastic carcinoma. Chin J Cancer Res. 2017;29(3):189-195.

Publication types

Substances

LinkOut - more resources